Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Radiation Biology
•
General Radiation Oncology
Now that we are using CBCT regularly, have there been any updates on dosimetry or second cancer risk?
Related Questions
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
When do you offer adjuvant radiation therapy for a glomus tumor of uncertain malignant potential of the extremity resected with negative margins?
Has there been an observed interaction between ACE inhibitors and development of angioedema in a block demarcated superficial radiation therapy treatment volume (ex. lip)?
What dose and fractionation would you use for a non-operable solitary fibrous tumor in the lumbar vertebra with definitive intent?
If an anatomical defect forms due to rapid disease response from pelvic radiation for large gynecological tumors, is it safe to proceed with a further radiotherapy boost
Would you ever re-irradiate the groin/inguinal region?
How do you manage a patient's pain from the skin tattoos placed at the CT simulation?
When do you prefer to use bolus for treating superficial tumors adjacent to or involving the skin surface, especially for complex surface anatomy in the pelvis, head/neck, and extremity regions?
How do you design pelvic lymph node treatment volumes for patients with tortuous or aberrant vascular anatomy?
Do you see MR Linac having a role in the treatment of CNS disease?
